Mountzios, Giannis http://orcid.org/0000-0002-7780-7836
Remon, Jordi
Hendriks, Lizza E. L. http://orcid.org/0000-0002-3521-2535
García-Campelo, Rosario
Rolfo, Christian http://orcid.org/0000-0002-5109-0267
Van Schil, Paul
Forde, Patrick M. http://orcid.org/0000-0001-6925-6344
Besse, Benjamin
Subbiah, Vivek http://orcid.org/0000-0002-6064-6837
Reck, Martin http://orcid.org/0000-0002-5348-4462
Soria, Jean-Charles
Peters, Solange
Article History
Accepted: 19 June 2023
First Online: 24 July 2023
Competing interests
: G.M. has acted as an adviser and/or consultant for Amgen, AstraZeneca, BMS, GSK, MSD, Novartis, Pfizer, Roche, Sanofi and Takeda; has received travel and accommodation fees from Amgen, AstraZeneca, BMS, GSK, Ipsen, MSD, Novartis, Roche, Sanofi and Takeda; and has been a principal investigator in clinical trials sponsored by Amgen, AstraZeneca, BMS, Gilead, GSK, Ιmmunomedics, Merck, MSD, Novartis, Roche and Sanofi. J.R. has acted as an adviser for Bayer, BMS, Boehringer Ingelheim, GenMab, Janssen, MSD and Takeda; has received speaker fees from Janssen and Pfizer; has received honoraria from MSD; and has received travel fees from AstraZeneca, BMS, OSE Immunotherapeutics and Roche. L.E.L.H. has received speaker fees from Benecke, Medtalks and VJOncology; has received personal fees from the committee that revised the Dutch guidelines on non-small-cell lung cancer, brain metastases and leptomeningeal metastases, AstraZeneca, Janssen and Roche; has received institutional fees from Amgen, AstraZeneca, Bayer, Beigene, BMS, Boehringer Eli Lilly, Ingelheim, high5oncology, Janssen, Merck, MSD, Novartis, Pfizer, Roche and Takeda; has received institutional research grants from AstraZeneca, Boehringer Ingelheim, Merck, Pfizer, Roche and Takeda; and has received institutional funding as a local principal investigator from AbbVie, AstraZeneca, Blueprint Medicines, Gilead, GSK, Merck Serono, Mirati, MSD, Novartis, Roche and Takeda. R.G.-C. has acted as an adviser and/or consultant for AstraZeneca, BMS, Eli Lilly, Janssen, MSD, Novartis, Pfizer, Roche, Sanofi and Takeda; has received speaker fees from AstraZeneca, BMS, Eli Lilly, Janssen, MSD, Novartis, Pfizer, Roche, Sanofi and Takeda; and has received research funding from BMS. C.R. has received consulting fees from Archer, Bayer, Boston Pharmaceuticals, Daiichi Sankyo, Eisai, EMD Serono, General Dynamics, Inviata, Janssen, Mirati, Novartis, Pfizer and Sanofi; has had stock options from Novartis; has been in the speaker’s bureau of AstraZeneca, COR2D, Guardanthealth, Intellisphere, MSD, Physician’s Education Resource, LLC and Roche; has received grant support from Pfizer; and has participated in the safety monitoring board of EMD Serono. P.V.S. is an adviser and/or has received honoraria for lectures from AstraZeneca, BMS, Janssen, MSD and Roche. P.M.F. receives institutional research funding from AstraZeneca, BMS, Corvus, Kyowa, Novartis and Regeneron; has been a consultant for Amgen, AstraZeneca, BMS, Daiichi, F-Star, G1, Roche Genentech, Janssen, Iteos, Merck, Novartis, Sanofi and Surface; and is a member of the data and safety monitoring board at Polaris. B.B. receives institutional grants from Abbvie, Amgen, AstraZeneca, Biogen, Blueprint Medicines, BMS, Celgene, Eli Lilly, GSK, Ignyta, Ipsen, Merck, MSD, Nektar, Onxeo, Pfizer, Pharma Mar, Sanofi, Spectrum Pharmaceuticals, Takeda and Tiziana Pharma. V.S. receives research funding and/or grant support for clinical trials from AbbVie, Agensys, Alfasigma, Altum, Amgen, Bayer, BERG Health, Blueprint Medicines, Boston Biomedical, Boston Pharmaceuticals, Celgene, D3 Bio, Dragonfly Therapeutics, Exelixis, Fujifilm, GSK, Idera Pharmaceuticals, Incyte Corporation, Inhibrx, Loxo Oncology, MedImmune, MultiVir, NanoCarrier, Northwest Biotherapeutics, Novartis, PharmaMar, Pfizer, Relay Therapeutics, Roche/Genentech, Takeda, Turning Point Therapeutics and Vegenics; has received travel support from Helsinn Healthcare, Incyte Corporation, Novartis and PharmaMar; has acted as a consultant and/or adviser for Eli Lilly, Helsinn Healthcare, Jazz Pharmaceuticals, Incyte Corporation, Loxo Oncology, MedImmune, Novartis, QED Therapeutics, Relay Therapeutics, Daiichi-Sankyo and R-Pharm; and has other relationships with Medscape. M.R. has received personal honoraria for lectures and consultancy from Amgen, AstraZeneca, Beigene, BMS, Boehringer Ingelheim, Daiichi Sankyo, GSK, Elli Lilly, Merck, Mirati, MSD, Novartis, Pfizer, Regeneron, Roche and Sanofi; is a paid member of the data monitoring committee for Daiichi-Sankyo and Sanofi; and has received travel and accommodation fees from Amgen, AstraZeneca, Beigene, BMS, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, GSK, Merck, Mirati, MSD, Novartis, Pfizer, Regeneron, Roche and Sanofi. J.-C.S. is a full-time employee at Amgen; and holds shares from Amgen, Gritstone Bio and Relay Therapeutics. S.P. has had consultant and/or advisory roles at AbbVie, Amgen, AstraZeneca, Bayer, Beigene, Biocartis, BMS, Boehringer Ingelheim, Clovis, Daiichi Sankyo, Debiopharm, ecancer, Eli Lilly, Foundation Medicine, Illumina, Imedex, Incyte, Janssen, Medscape, Merck Serono, Merrimack, MSD, Novartis, Pharma Mar, Phosplatin Therapeutics, Pfizer, Regeneron, Roche/Genentech, Sanofi, Seattle Genetics and Takeda; has been a speaker for AstraZeneca, BMS, Boehringer Ingelheim, ecancer, Eli Lilly, Illumina, Imedex, Medscape, Merck Sharp and Dohme, Novartis, Pfizer, Prime, Roche/Genentech, Sanofi and Takeda; and has received institutional grants and/or institutional financial support for clinical trials sponsored by Amgen, AstraZeneca, Biodesix, BMS, Boehringer Ingelheim, Clovis, Eli Lilly, GSK, Illumina, Merck Serono, Mirati, MSD, Novartis, Pfizer, Phosplatin Therapeutics and Roche/Genentech.